Immunotherapy-Based Regimen Boosts PFS in EGFR-Mutant Lung Cancer

(MedPage Today) -- Combining the PD-1 inhibitor sintilimab with a bevacizumab biosimilar and chemotherapy significantly improved progression-free survival (PFS) versus chemotherapy alone in patients with EGFR-mutant nonsquamous non-small cell lung...